Over the past two decades, measurements of carbon nanotube toxicity and biodistribution have yielded a wide 8 range of results. Properties such as nanotube type (single-walled vs. multi-walled), purity, length, aggregation 9 state, and functionalization, as well as route of administration, greatly affect both the biocompatibility and 10 biodistribution of carbon nanotubes. These differences suggest that generalizable conclusions may be elusive 11 and that studies must be material-and application-specific. Here, we assess the short-and long-term 12 biodistribution and biocompatibility of a single-chirality DNA-encapsulated single-walled carbon nanotube 13 complex upon intravenous administration that was previously shown to function as an in-vivo reporter of 14 endolysosomal lipid accumulation. Regarding biodistribution and fate, we found bulk specificity to the liver and 15 >90% signal attenuation by 14 days in mice. Using near-infrared hyperspectral microscopy to measure single 16 nanotubes, we found low-level, long-term persistence in organs such as the heart, liver, lung, kidney, and 17 spleen. Measurements of histology, animal weight, complete blood count, and biomarkers of organ function all 18 suggest short-and long-term biocompatibility. This work suggests that carbon nanotubes can be used as 19 preclinical research tools in-vivo without affecting acute or long-term health. 20
75 1 mg/mL of raw EG 150X single walled carbon nanotubes purchased from Chasm Advanced Materials 76 (Norman, Oklahoma) were mixed with 2 mg/mL ssDNA in 0.1 M NaCl. SWCNTs were then wrapped in 77 ssDNA via probe tip ultrasonication (Sonics & Materials, Inc.) for 120 minutes at ~ 8 W. Dispersions were then 78 centrifuged (Eppendorf 5430 R) for 90 minutes at 17,000 x g. The top 85% of the resulting supernatant was 79 then collected and used for purification of the (9,4) chirality. 80 Purification of the (9,4) nanotube from the unsorted ssCTTC 3 TTC-SWCNT sample was performed using 81 the aqueous two-phase extraction method [18] [19] [20] . In brief, ssCTTC 3 TTC-SWCNT was mixed with a solution 82 containing a final concentration of 7.76% polyethylene glycol (PEG, molecular weight 6 kDa, Alfa Aesar), and 83 15.0% polyacrylamide (PAM, molecular weight 10 kDa, Sigma Aldrich). Following an overnight incubation at 84 room temperature, the sample was vortexed and then centrifuged at 10,000 x g for 3 minutes. The top phase of 85 the resulting solution was then collected and added to blank "bottom phase," which was produced by removing 86 the bottom phase of a 7.76 PEG, 15.0% PAM solution following centrifugation at 10,000 x g for 10 minutes. 87 The resulting solution was once again vortexed and centrifuged to produce a top phase enriched in 88 ssCTTC 3 TTC-(9,4) complexes. Following collection of the top phase NaSCN was added at a final concentration 89 of 0.5 M. This solution was then incubated overnight at 4 degrees Celsius to precipitate ssCTTC 3 TTC- (9, 4) . 90 The sample was then centrifuged at 17,000 x g for 20 minutes, causing ssCTTC 3 TTC-(9,4) to pellet. Following 91 removal of the supernatant, this pellet was then suspended in diH 2 O and stored with 0.1 mg/mL free 92 ssCTTC 3 TTC-(9,4). All animal studies were approved and carried out in accordance with the Memorial Sloan Kettering Cancer 95 Center Institutional Animal Care and Use Committee. All animals used in the study were male C57BL/6 mice at 5 96 6-12 weeks of age. All control and experimental mice were age matched and housed in identical environments.
97
For the assessment of ssCTTC 3 TTC-(9,4) in vivo, mice were tail vein injected with 200 µL of 0.5mg/L 98 ssCTTC 3 TTC-(9,4) diluted in PBS. For all other experiments, mice were tail vein injected with 200 µL of 1.0 99 mg/L ssCTTC 3 TTC-(9,4) diluted in PBS. For in vivo spectroscopy, mice were anesthetized with 2% isoflurane 100 prior to data collection. was removed via long pass filters, and the emission was focused through a 410 µm slit into a Czerny-Turner 108 spectrograph with 303 mm focal length (Shamrock 303i, Andor). The beam was dispersed by an 85 g/mm 109 grating with 1350 nm blaze wavelength and collected by an iDus InGaAs camera (Andor). After acquisition,
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data was processed to apply spectral corrections for non-linearity of the InGaAs detector response, background 111 subtraction, and baseline subtraction via the use of OriginPro 9 software with a standard adjacent averaging 112 smoothing method and a spline interpolation method. Near-infrared hyperspectral microscopy was performed as previously described 23 . In brief, a continuous 120 wave 730 nm diode laser (output power = 2 W) was injected into a multimode fiber to provide an excitation 121 source. After passing through a beam shaping optics module to produce a top hat intensity profile (maximum 122 20% variation on the surface of the sample), the laser was reflected through an inverted microscope (with complexes were found to localize to the liver of mice following intravenous injection, where it was non-144 invasively assessed via a fiber optic probe 17 . Spectra of the nanotube photoluminescence in mice were acquired 145 using a fiber optic probe-coupled spectrometer and near-infrared camera (described in Methods). The 146 measurements found a sharp decrease in nantoube fluorescence intensity over two weeks after injection ( Figure   147 1). This result suggests that nanotubes were either quenched or excreted from the liver over this time period. 
Microscopy and histology of SWCNTs in resected murine tissues 155
To further investigate the biodistribution of ssCTTC 3 TTC-(9,4) DNA-nanotube complexes following 156 intravenous injection, we examined tissue sections via near-infrared hyperspectral microscopy. This technique 157 can image single SWCNTs 24 in tissues even in the presence of normal tissue autofluorescence [25] [26] [27] . We resected 158 and paraffinized tissue sections of heart, liver, lung, kidney, spleen and brain 24 hours after administration of 159 SWCNTs and imaged using the near-infrared hyperspectral microscope at 100X magnification. Upon 160 investigation of the near-infrared data, individual ROIs, denoting ssCTTC 3 TTC-(9,4) complexes, could be 161 detected in liver, spleen, lung, kidney and heart, with highest prevalence in liver and spleen ( Figure 2 ). The 162 same tissues were also processed via H&E staining ( Figure 2 ). The stained tissues were assessed by a trained 163 pathologist; no signs of tissue injury or other abnormalities were found. No signal was detected in the brain via We also assessed the long-term biodistribution of the nanotubes. Previous studies found the persistence of 166 non-covalently functionalized SWCNTs in organs, such as the liver and spleen, for several months 16 . We used 167 near-infrared hyperspectral microscopy to assess the long term biodistribution of ssCTTC 3 TTC-(9,4) in heart, 168 liver, lung, kidney, and spleen tissue. One month following injection, nanotube emission could be seen in all 169 tissue sections (Figure 3) . The nanotubes were sparsely distributed through lung, heart, and kidney tissue, and 170 more prevalent in the liver and spleen. Upon observation of the H&E stained tissue sections (Figure 3 ), no 171 abnormalities were noted by a trained pathologist.
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Murine tissues were also assessed at three and five months after injection. No nanotubes were found in lung 173 tissue at the three-month timepoint (Figure 4 ), or in lung or heart tissue at five months ( Figure 5 ), although they 174 were found in the liver, spleen, and kidneys at both timepoints. Despite chronic exposure to ssCTTC 3 TTC-(9,4) 175 in these organs, no tissue abnormalities were observed upon histological inspection of these tissues by a trained 
Serum biomarker assessments 206
To further assess the effects of short and long-term exposure of the DNA-nanotube complexes, serum 207 biomarkers, and complete blood counts were measured 24 hours and five months after administration of the 208 nanotubes. Biomarkers of hepatic injury were measured 24 hours and 5 months after injection of 10 209 ssCTTC 3 TTC-(9,4). Between nanotube and PBS injected mice, no statistically significant differences were 210 found for the biomarkers alanine aminotransferase (ALT), aspartate aminotransferase (AST), globulin (GLOB), 211 albumin (ALB), total protein, or TCO 2 ( Figure S1 ). A small, statistically significant increase was apparent in 212 serum levels of serum alkaline phosphatase (Figure 7 ). However this slight difference is likely not biologically 213 significant, as the values seen for nanotube injected mice here are consistent with those seen in another study 214 that assessed ALP levels in similarly aged, male C57BL/6 mice injected with PBS 17 . A statistically significant 215 difference is also apparent in the ALB:GLOB ratio in serum; this difference is slight and likely due to 216 instrument limitations, as inspection of the raw data reveals that limited resolution in ALB:GLOB 217 measurements is likely the cause for this significant difference (Figure 7) . Despite the presence of nanotubes in 218 the liver 5 months after injection, no signs of liver injury were evident from hepatic biomarkers (Figure 8 ). globulin (GLOB) levels in mice. G) Serum ALB:GLOB ratio in mice. H) Serum total protein levels in mice.
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Statistical significance was determined with a Student's two way t-test. N=3 mice per group.
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Serum biomarkers of renal function were assessed 24 hours and five months after injection of the 237 nanotube complexes. Between nanotube-injected and control mice after 24 hours, no statistically significant 238 differences were found for the biomarkers blood urea nitrogen (BUN), creatinine (CREA), BUN:CREA, 239 phosphate (P), sodium (Na), Na:K, and anion gap (Figure 9 ). While chloride levels were raised in nanotube-240 injected mice, the increase was less than 2% (Figure 9 ). Potassium (K) levels were also different between the 241 two groups, although they were actually lower in nanotube injected mice (Figure 9 ) which is not a sign of renal 242 injury (an increase in K levels would be). Finally, a significant difference was seen in the Na:K ratio between 243 groups. A decrease in this ratio is indicative of liver/kidney stress, however, rather than the slight increase seen 244 herein (Figure 9 ). Overall, biomarkers of renal function at 24 hours suggest that the nanotubes did not cause any ). Blood counts associated with oxygen levels appeared normal; significant differences were not seen in red 274 blood cell (RBC) counts, hemoglobin levels, hematocrit percentage, mean corpuscular hemoglobin quantity or 275 concentration, or RBC distribution width (Figure 12) . A slight, statically significant decrease was seen in 276 platelet count between groups. This difference was not apparent at 5 months after administration (Figure 13 ).
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The complete blood count 5 months after injection with nanotubes, shows no significant differences between 278 control and nanotube-injected mice (Figure 14-15 ). Overall, the results suggest minimal effects of nanotubes on 
Conclusion

317
In this work, we investigated the short and long term biodistribution and biocompatibility of a purified 318 DNA-encapsulated single-walled carbon nanotube complex consisting of an individual nanotube chirality, 319 administered intravenously. Bulk biodistribution measurements in mice found that, consistent with previous 320 studies on similar complexes, the nanotubes localized predominantly to the liver. Using near-infrared 321 hyperspectral microscopy to image single nanotube complexes, nanotube complexes were found in other organs 322 such as the kidney, spleen, hearts, and lungs and persisted in some organs at for up to 5 months. The results 323 showed that this reporter was highly biocompatible overall, although future studies are warranted to more 324 carefully assess long-term impact on organ function. Tissue histology and mouse weight measurements showed 325 no differences upon administration of nanotubes. Measurements of serum biomarkers, including complete blood 326 count, renal biomarkers, and hepatic markers showed negligible changes by the presence of carbon nanotubes < 15 327 4 months, and minor changes in renal markers at 5 months. These results indicate that carbon nanotubes, used in 328 preclinical studies under the preparation conditions and concentrations herein, do not cause any appreciable 329 signs of toxicities at time points less than 4 months. The work suggests that these materials are unlikely to cause 330 significant problems in applications such as preclinical research, drug screening, and drug development.
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However, the long-term persistence of nanotubes in tissues suggests that additional assessments are warranted 332 to assess the potential for use in humans. In general, these studies also suggest, in light of previous works, that 333 carbon nanomaterial biodistribution and biocompatibility are specific to carbon nanotube type, purity, 334 functionalization, and route of administration. This issue has implications pertinent to the wider perception and 335 applicability of nanomaterials. 
